Results 31 to 40 of about 58,085 (295)

Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes

JAMA dermatology, 2019
Importance Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with an increased risk of developing bullous pemphigoid (BP).
Seon Gu Lee, Hee-Jung Lee, M. Yoon, D. H. Kim   +3 more
semanticscholar   +1 more source

Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. [PDF]

, 2015
The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients.
Abe, Yosuke, Akiba, Yasutada, Fujiwara, Kaori, Fukunishi, Shinya, Higuchi, Kazuhide, Iguchi, Munetaka, Inoue, Takuya, Ishida, Kumi, Kakimoto, Kazuki, Kaunitz, Jonathan D, Masuda, Daisuke, Narabayashi, Ken, Nouda, Sadaharu, Okada, Toshihiko, Sakanaka, Taisuke, Takeuchi, Toshihisa, Umegaki, Eiji, Yorifuji, Naoki   +17 more
core   +1 more source

The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum [PDF]

, 2004
The discovery of a potentially novel proline-specific peptidase from bovine serum is presented which is capable of cleaving the dipeptidyl peptidase IV (DPIV) substrate Gly-Pro-MCA.
Abbott, Birney, Cunningham, De Meester, De Meester, Duke-Cohan, Duke-Cohan, Duke-Cohan, Durinx, Gilmartin, Hegen, Hopsu-Havu, Huang, Iwaki-Egawa, Kin, Laemmli, Malik, Mentlein, Mentlein, Ohkubo, Ohnishi, Pineiro-Sanchez, Scanlan, Schon, Sedo, Sedo, Shibuya-Saruta, Smith, Stockel-Maschek, Underwood, Yaron, Yoshimoto   +31 more
core   +1 more source

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Frontiers in Immunology, 2022
Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto   +8 more
doaj   +1 more source

DPP-4 inhibitor dose selection according to manufacturer specifications:A Contemporary Experience From UK General Practice [PDF]

, 2019
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests.
Busse, Michael, Gollop, Nicholas D., Marcus, Michael W., Spanopoulos, Dionysis, Tebboth, Abigail, Webb, Joanne   +5 more
core   +1 more source

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats

Journal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki, Takao Nakajima, Kimihisa Ueno, Yuji Nomoto, Katsuya Higo   +4 more
doaj   +1 more source

Seprase: An overview of an important matrix serine protease [PDF]

, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
Abbott, Abbott, Abbott, Acharya, Adams, Adams, Aertgeerts, Aimes, Alcolado, Aoyama, Ariga, Artym, Bangert, Barrett, Bauvois, Bermpohl, Birney, Bissell, Brendan F. O'Connor, Brown, Busek, Chen, Chen, Chen, Chen, Cheng, Cheng, Christiansen, Collins, Corpet, De Wever, Del Rosso, Dolznig, Dvorak, Edosada, Edosada, Fassnacht, Fidler, Fink, Flentke, Fulop, Garcia-Horsman, Garin-Chesa, Gerner, Ghersi, Ghersi, Ghersi, Gilmore, Goldstein, Goldstein, Goodman, Gorrell, Guex, Hofheinz, Huang, Huber, Huber, Ibrahim, Iwasa, Jin, Kelly, Kelly, Kelly, Kelly, Kloft, Koyama, Lee, Lee, Lee, Lee, Lee, Levy, Levy, Levy, Loeffler, Mathew, Mersmann, Milner, Monsky, Mori, Mueller, Nicholas, Niedermeyer, Niedermeyer, Niedermeyer, Oertel, Okada, Okada, Ollis, Pamela O'Brien, Park, Pineiro-Sanchez, Ramirez-Montagut, Rennex, Rettig, Rettig, Rettig, Rettig, Rosenblum, Samel, Scanlan, Schechter, Scott, Scott, Sieweke, Skubitz, Stremenova, Sun, Tahtis, Tran, Wang, Wang, Welt, Welt, Wesley, Zhang   +115 more
core   +1 more source

Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway

Cell Death Discovery, 2021
As a common chronic metabolic disease, the development of diabetes mellitus (DM) may also be accompanied by liver damage and inflammatory disorders. Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP4, also known as CD26), which is clinically ...
Xin Wang, Jing Ke, Yingchun Zhu, Bin Cao, Rui-li Yin, Yan Wang, Ling Wei, Li-jie Zhang, Long-yan Yang, Dong Zhao   +9 more
semanticscholar   +1 more source

[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Leprdb/db type 2 diabetic mice [PDF]

, 2017
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give ...
Akhter, Farjana, Hannan, J.M.A., Hossain, Mohammad Tashnim, Kabir, Ashraf Ul, Mahzabeen, Sinayat, Mohsin, Md. Nurul Absar Bin, Muna, Ishrat Aklima, Razu, Bodiul Alam, Samad, Mehdi Bin, Unnoor, Naziat   +9 more
core   +2 more sources

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Journal of Medical Case Reports, 2018
Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of ...
Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada   +12 more
doaj   +1 more source